The most telling number in European venture capital this week was not the largest one. Tandem Health's €86.49 million ($100 million) Series B, reported by EU-Startups, is a substantial round by any regional standard, and it confirms that Stockholm remains capable of producing companies that attract growth-stage capital. But the more revealing detail is who led it: the Scaleup Europe Fund, managed by EQT, a vehicle created precisely because European founders have long complained that the money to go from promising to dominant tends to arrive with an American area code. That a European-managed fund is now writing nine-figure cheques into an AI healthcare company is a small piece of evidence that the continent's much-discussed scale-up gap is being addressed with actual capital rather than policy papers. Set against that headline deal, the rest of the week's activity reads like a cross-section of what European venture has become: a concentration of conviction in healthcare, a quieter but persistent appetite for infrastructure and financial plumbing, an unusual reliance on public and quasi-public money at the earliest stages, and a growing awareness that the froth around artificial intelligence carries real financial risk. Why this matters for the European ecosystem The European venture market has spent the better part of three years recalibrating from the 2021 peak. Deal counts fell, valuations compressed and growth-stage rounds in particular became scarce as crossover investors retreated to public markets. The question that has hung over the ecosystem since is whether Europe can build a self-sustaining pipeline of capital from seed through to exit, or whether it will remain a feeder system that produces companies for others to fund and eventually acquire. The deals surfaced by EU-Startups this week offer a partial answer. They span Brussels, Zurich, Stockholm and Zug, four cities that rarely appear in the same sentence as Silicon Valley, and they involve a lead investor roster that is almost entirely European: BlackFin Capital Partners, EQT, CDP Venture Capital, Kinnevik, Northzone. That geographic and institutional diversity is itself a development. A decade ago, a round of this size for a Nordic healthtech firm would very likely have been led from London, New York or San Francisco. The counterpoint comes from Bloomberg Markets, which reported that global equities fell after leaders of the largest artificial-intelligence firms proposed slowing the technology's development. Nasdaq 100 futures dropped 1.4 percent, and SoftBank Group, the most prominent backer of OpenAI, recorded its steepest decline in three months. Tech stocks led the declines as traders worried that any effort to rein in frontier AI could undermine the capital expenditure boom underpinning the sector. For European venture investors, many of whom have spent the past eighteen months rebranding portfolio companies as AI businesses, this is a reminder that the AI premium is not a permanent feature of the landscape. Healthcare as Europe's AI wedge The most consistent thread running through the week's funding is healthcare, and specifically the application of AI to clinical workflows and diagnostics. Tandem Health, which describes its product as a complete AI medical assistant for European clinics, is building what EU-Startups characterises as an AI-native operating system for European healthcare. The company had already raised a round in June 2025 and has now secured $100 million with backing from Kinnevik, Northzone, Amino Collective and Visionaries alongside EQT's Scaleup Europe Fund. Aeon, based in Zurich, provides a different angle on the same thesis. EU-Startups reports exclusively that the company has closed a seed extension that brings its total seed funding above €12 million ($14 million), building on an €8.2 million raise in June 2025, and has simultaneously acquired Aware Health, a German blood diagnostics platform. Aeon's product is AI-powered whole-body health check-ups, a preventive model that sits outside traditional reimbursed care and therefore avoids some of the procurement friction that slows healthtech adoption in Europe. The strategic logic is coherent. Europe's fragmented, largely public healthcare systems are an awkward market for consumer-facing AI, but they are a natural fit for tools that reduce administrative load on clinicians and for premium preventive services sold directly to individuals or employers. European founders also benefit from regulatory familiarity: the EU's medical device rules and data protection regime are obstacles to American entrants and moats for local companies that have already navigated them. Investors appear to have concluded that if Europe is going to produce category-defining AI companies, healthcare is one of the few verticals where regional incumbency is an